Skip to main content
Premium Trial:

Request an Annual Quote

Agencourt to Continue Providing Genomic Services to NIH

NEW YORK, Aug. 31 (GenomeWeb News) - Agencourt Bioscience said today that the National Institutes of Health has renewed its contract with the company for genomic sequencing services.


Under the terms of the two-year agreement, Agencourt will provide ESTs (expressed sequence tags) and SAGE (serial analysis of gene expression) to the NIH Mammalian Gene Collection and Cancer Genome Anatomy projects. The original contract began in January 2002 and runs through the end of this year.


The goal of the MGC project is to identify and sequence representative full open reading frame cDNA clones for all human and mouse genes, and select rat genes. Agencourt said that it has sequenced more than 1.3 million cDNA ESTs to aid in the identification of these clones, and that it will continue to sequence such tags for the MGC project.


The primary goals of the cancer genome anatomy project are to map, evaluate, and sequence genes of cells at various stages of cancer growth. Agencourt said it is responsible for sequencing the project's SAGE libraries to quantify gene expression within the cells.


Agencourt said it will make all data generated for the projects publicly available.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.